| Abstract | Biologic disease-modifying antirheumatic drugs have been proven effective in the treatment of rheumatoid arthritis, but their efficacy literally comes at quite a high price to health plans. Therefore, MCOs are examining various strategies to provide coverage for these agents in a more cost-effective manner. |
| Authors | Jaan Sidorov
(Affiliation: Geisinger Health System, Danville, Pennsylvania, USA. jaans at aol.com)
|
| Journal | Managed care interface
(Manag Care Interface)
Vol. 20
Issue 7
Pg. 28-30
(Jul 2007)
ISSN: 1096-5645 United States |
| PMID | 17849731
(Publication Type: Journal Article)
|
| Chemical References |
|
| Topics |
- Antirheumatic Agents
(economics, therapeutic use)
- Arthritis, Rheumatoid
(drug therapy)
- Biological Therapy
- Humans
- Insurance Coverage
- Managed Care Programs
- United States
|
